- Overstock.com, Inc. (OSTK) Stumbles After Reported Q3 2020 Financial Results
- What's the Analyst Recommendation for Rekor Systems Inc. (REKR)?
- Let’s Take a Look at Bunge Limited (BG) Stock
- Is it Time to Sell/Buy Callaway Golf Company (ELY) Stock After Recent Trade?
- Generac Holdings Inc. (GNRC) is up 115.84% this year
AMAG Pharmaceuticals Inc. (AMAG) share price soared 1.41% with the closing price of $13.64 on Thursday. AMAG Pharmaceuticals Inc. stock has an exchanging volume of 4.42 million shares, which is high, contrasted with its 3-months average volume of 1.34M shares. Its market capitalization has now reached to $471.26M and analysts have a consensus target price of $11.96 in the 12-month period.
Barclays announced it was Downgrade coverage of AMAG Pharmaceuticals Inc. in a research note on August 18, 2020. Piper Jaffray rated the stock as an Underweight in a research noted published on October 30, 2019. H.C. Wainwright rated the stock as a Buy in a research note published on August 01, 2019.
Covis Group S.à r.l. Announces Commencement of Tender Offer for All Outstanding Shares of AMAG Pharmaceuticals, Inc.on October 15, 2020 news published at Yahoo.
Covis Group S.à r.l. declared the commencement of a cash tender offer to purchase all of the outstanding shares of common stock of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (“AMAG”). The tender offer is being made pursuant to the merger agreement (the “Merger Agreement”) announced by Covis and AMAG on October 1, 2020 under which Covis has agreed to acquire AMAG for $13.75 per share. The transaction has a total enterprise value of approximately $647 million, including net debt.
The $13.75 per share all-cash tender offer represents a premium of approximately 46% over AMAG’s closing stock price on September 30, 2020, the last full trading day prior to the announcement.
A tender offer statement on Schedule TO that includes the Offer to Purchase and related Letter of Transmittal that set forth the terms and conditions of the tender offer will be filed today by Covis and its subsidiary that will be making the offer. Additionally, AMAG will file with the U.S. Securities and Exchange Commission (the “SEC”) a solicitation/recommendation statement on Schedule 14D-9 that includes the recommendation of AMAG’s board of directors that AMAG stockholders tender their shares in the tender offer.
The tender offer will expire at 12:00 midnight (New York City time) on November 12, 2020 (one minute after 11:59 P.M. New York City time on November 12, 2020), unless the offer period is extended in accordance with the Merger Agreement and the applicable rules and regulations of the SEC. The completion of the tender offer will be conditioned on AMAG’s stockholders tendering at least a majority of AMAG’s outstanding shares and other customary closing conditions.
If, as a result of the tender offer, the stockholders tender at least one share more than 50% of the then outstanding shares of AMAG’s common stock, the subsidiary of Covis will, subject to the satisfaction or waiver of the remaining conditions set forth in the Merger Agreement, merge with and into AMAG, with AMAG surviving as an indirect wholly owned subsidiary of Covis, under Section 251(h) of the Delaware General Corporation Law, without prior notice to, or any action by, any other stockholder of AMAG, as soon as practicable following the consummation of the tender offer.
AMAG Past Trading Activity
The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, AMAG price has rose by 2.17%. In the course of past three months sees the stock go up around 62.38%, while it has gain 82.35% over the past six months and 12.08% since the start of the year.
AMAG Earning History
Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), the firm recorded a revenue of 52.76 billion, which was higher than the gauge of 60.53M made by certain experts. For that equivalent quarter, AMAG Pharmaceuticals Inc. posted -$0.23 earnings per share (EPS) which was underneath the consensus estimate of -$0.19 by -$0.04, which represents to a reduction by -21.10%.
AMAG Price Performance
Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on AMAG Pharmaceuticals Inc. has seen its stock exchanging -1.16% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +64.54% above its three-month low. A more extensive look sees AMAG exchanging -1.16% beneath its 52-week high and 209.30% above from its 52-week low price.
AMAG Instability & Beta Factor
The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 0.91%, while it has a month to month instability of 3.80%. The company has an ATR (Average True Range) of 0.53 and a beta factor of 1.13.